Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cord blood mononuclear cells for ischemic stroke
ChiCTR2400084406Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- May 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of umbilical cord blood mononuclear cells in ischemic stroke, sponsored by The First Hospital of Hebei Medical University. Primary endpoint: Modified Rankin Scale. Planned start May 2024; status: not yet recruiting.
02
Drugs
umbilical cord blood mononuclear cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2400084406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084406.